^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial
Published date:
09/22/2020
Excerpt:
The addition of erlotinib significantly improved OS (median, 39.4 vs 27.4 months; HR, 0.75; P = 0.025). Patients with overexpressing EGFR treated with erlotinib had a better OS and PFS than those without erlotinib....Concurrent chemoradiotherapy with ENI and/or erlotinib improved long-term survival in locally advanced ESCC.
Secondary therapy:
cisplatin + paclitaxel
DOI:
10.1038/s41416-020-01054-6
Trial ID:
